Gilead GIO-Med 2019 Roadshow Cardiff

An introduction to CAR-T in the UK

Thursday 12 September 2019

Miskin Manor Hotel,
United Kingdom


This one-day meeting, chaired by Professor Chris Fegan (Cardiff University) will feature a unique faculty of international experts presenting live in the room in Cardiff and broadcast in to the meeting via webcast from other locations in the UK. Topics will include;

  • An overview of CAR-T therapy including the science behind the therapy.
  • An examination of UK patient selection guidelines.
  • Discussion and debate asking ‘Will CAR-T replace stem cell therapy?’
  • A review of primary mediastinal large B-cell lymphoma & national guidelines and finally...
  • A reality check… What about patients who can’t take CAR-T therapy?

Professor Christopher Fegan
Consultant Haematologist,
University Hospital of Wales,
Cardiff, UK


The full programme can be viewed HERE

Who should attend?
This meeting is ideal for:
  • Consultants
  • Pharmacists
  • Nurses
  • Researchers and
  • Scientists

and any healthcare professionals who have an interest in the future shape and direction of CAR-T therapy and research.


An introduction to CAR-T in the UK - Cardiff has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 4 category 1 (external) CPD credit(s). Please note, CPD credits obtained through RCP will be accepted by other medical colleges such as the Royal College of Pathologists and the Royal College of Nursing. 

When & Where
9:00 am - 3:30 pm - Thursday, 12 September 2019
Miskin Manor Hotel
Talbot Green
CF72 8ND 
Map here
Parking: Onsite at the hotel.


The meeting costs are underwritten by Gilead Sciences Ltd. and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity. 

Date of preparation: June 2019  
This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.